ASR Vermogensbeheer N.V. Boosts Stake in Pfizer Inc. $PFE

ASR Vermogensbeheer N.V. grew its position in shares of Pfizer Inc. (NYSE:PFE) by 1.9% during the second quarter, according to its most recent filing with the SEC. The firm owned 609,397 shares of the biopharmaceutical company’s stock after acquiring an additional 11,443 shares during the period. ASR Vermogensbeheer N.V.’s holdings in Pfizer were worth $14,771,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. GKV Capital Management Co. Inc. purchased a new stake in shares of Pfizer in the 1st quarter worth approximately $27,000. North Capital Inc. purchased a new stake in shares of Pfizer in the 1st quarter worth approximately $28,000. Bayforest Capital Ltd purchased a new stake in shares of Pfizer in the 1st quarter worth approximately $28,000. Horizon Financial Services LLC purchased a new stake in shares of Pfizer in the 1st quarter worth approximately $35,000. Finally, WPG Advisers LLC purchased a new stake in shares of Pfizer in the 1st quarter worth approximately $35,000. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts recently weighed in on the company. Bank of America upped their price target on Pfizer from $27.00 to $28.00 and gave the stock a “neutral” rating in a research note on Wednesday, August 6th. Wall Street Zen cut Pfizer from a “buy” rating to a “hold” rating in a research report on Sunday. Morgan Stanley upped their price objective on Pfizer from $32.00 to $33.00 and gave the company an “equal weight” rating in a research report on Wednesday, August 6th. Citigroup upped their price objective on Pfizer from $25.00 to $26.00 and gave the company a “neutral” rating in a research report on Wednesday, August 6th. Finally, UBS Group reaffirmed a “neutral” rating and issued a $28.00 price objective on shares of Pfizer in a research report on Wednesday. Two investment analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, eleven have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $28.29.

Pfizer Price Performance

NYSE PFE opened at $27.21 on Thursday. The business’s fifty day moving average price is $24.59 and its 200-day moving average price is $24.14. The stock has a market capitalization of $154.68 billion, a price-to-earnings ratio of 14.47, a PEG ratio of 0.82 and a beta of 0.55. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.16 and a quick ratio of 0.85. Pfizer Inc. has a 1-year low of $20.92 and a 1-year high of $30.43.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, beating the consensus estimate of $0.58 by $0.20. The firm had revenue of $14.65 billion for the quarter, compared to analysts’ expectations of $13.43 billion. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The company’s revenue was up 10.3% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.60 EPS. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. On average, equities analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.